Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1967 2
1968 1
1971 1
1973 3
1975 1
1976 1
1977 2
1982 1
1985 1
1987 1
1988 1
1989 6
1990 7
1991 2
1992 2
1993 2
1994 4
1995 9
1996 9
1997 7
1998 10
1999 13
2000 12
2001 11
2002 7
2003 8
2004 6
2005 9
2006 18
2007 6
2008 13
2009 10
2010 12
2011 17
2012 14
2013 5
2014 12
2015 4
2016 12
2017 13
2018 6
2019 7
2020 12
2021 12
2022 13
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Moreau P, et al. Among authors: berenson jr. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29866475 Clinical Trial.
Carfilzomib in multiple myeloma.
Andreu-Vieyra C, Berenson JR. Andreu-Vieyra C, et al. Among authors: berenson jr. Expert Opin Biol Ther. 2014 Nov;14(11):1685-99. doi: 10.1517/14712598.2014.953050. Epub 2014 Aug 29. Expert Opin Biol Ther. 2014. PMID: 25170966 Review.
Monitoring multiple myeloma.
Udd KA, Spektor TM, Berenson JR. Udd KA, et al. Among authors: berenson jr. Clin Adv Hematol Oncol. 2017 Dec;15(12):951-961. Clin Adv Hematol Oncol. 2017. PMID: 29315287
The role of JAK inhibitors in multiple myeloma.
Ghermezi M, Spektor TM, Berenson JR. Ghermezi M, et al. Among authors: berenson jr. Clin Adv Hematol Oncol. 2019 Sep;17(9):500-505. Clin Adv Hematol Oncol. 2019. PMID: 31549971 Review.
Procainamide-associated pancytopenia.
Shields AF, Berenson JA. Shields AF, et al. Among authors: berenson ja. Am J Hematol. 1988 Apr;27(4):299-301. doi: 10.1002/ajh.2830270413. Am J Hematol. 1988. PMID: 3354563
Myeloma bone disease.
Berenson JR. Berenson JR. Best Pract Res Clin Haematol. 2005;18(4):653-72. doi: 10.1016/j.beha.2005.03.001. Best Pract Res Clin Haematol. 2005. PMID: 16026743 Review.
Myeloma--the therapeutic challenge.
Berenson JR. Berenson JR. Med Klin (Munich). 2000 Oct 15;95 Suppl 2:19-21. Med Klin (Munich). 2000. PMID: 11089383 Review.
Pathophysiology of bone metastases.
Berenson JR, Rajdev L, Broder M. Berenson JR, et al. Cancer Biol Ther. 2006 Sep;5(9):1078-81. doi: 10.4161/cbt.5.9.3306. Epub 2006 Sep 20. Cancer Biol Ther. 2006. PMID: 17012831 Review.
Management of bone disease in multiple myeloma.
Terpos E, Berenson J, Raje N, Roodman GD. Terpos E, et al. Among authors: berenson j. Expert Rev Hematol. 2014 Feb;7(1):113-25. doi: 10.1586/17474086.2013.874943. Epub 2014 Jan 16. Expert Rev Hematol. 2014. PMID: 24433088 Review.
304 results